Sherri Arledge, MD
Hematology & Oncology · Mobile, ALNPI 1881805406
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 1,031 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations.
Across 1,031 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AstraZeneca$2K
- Merck$1K
- Astellas Pharma US Inc$1K
- E.r. Squibb & Sons, L.L.C.$945
- Genentech USA, Inc.$869
- plus $11K from 54 others
Across 16 payments — averaging $21,176 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$327K
- E.r. Squibb & Sons, L.L.C.$7K
- AstraZeneca$5K
What the payments were for
- Consulting fees$1751%
- Speaking & faculty fees$1501%
- Food & beverage$18,17995%
- Education$7294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,232 in reported general payments places this provider in the 75th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 33 | $895,950 |
| JakafiRuxolitinib Phosphate | 48 | $681,107 |
| RevlimidLenalidomide | 35 | $659,020 |
| Lenalidomide | 48 | $635,833 |
| BrukinsaZanubrutinib | 34 | $463,979 |
| ImbruvicaIbrutinib | 24 | $379,064 |
| PomalystPomalidomide | 16 | $375,760 |
| VerzenioAbemaciclib | 24 | $353,361 |
| IbrancePalbociclib | 12 | $177,510 |
| KrazatiAdagrasib | 12 | $166,562 |
| BosulifBosutinib | 14 | $162,953 |
| XtandiEnzalutamide | 11 | $151,259 |
| VenclextaVenetoclax | 12 | $93,612 |
| SancusoGranisetron | 31 | $86,197 |
| EliquisApixaban | 35 | $31,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $258 | $895,95033 claims |
| Incyte CorporationJakafi | $770 | $681,10748 claims |
| Bristol Myers SquibbRevlimid | $589 | $659,02035 claims |
| Beigene USA, Inc.Brukinsa | $148 | $463,97934 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $72 | $379,06424 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $945 | $375,76016 claims |
| PfizerIbrance, Bosulif, Eliquis | $832 | $372,00761 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $679 | $354,04569 claims |
| Astellas Pharma US IncXtandi, Veozah | $1,056 | $159,21326 claims |
| AbbVieVenclexta | $255 | $93,61212 claims |
| Cumberland Pharmaceuticals, Inc.Sancuso | $31 | $86,19731 claims |
| Johnson & JohnsonXarelto | $667 | $14,44318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Mobile
- Anita MazloomMobile$20K
- Daniel CameronMobile$17K
- Jose Galeas SorianoMobile$17K
- Michael MeshadMobile$14K
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.